References & further readingPrimary sources cited on this page
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) analogue of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is on the World Health Organisation's International Nonproprietary Names list. Semax is registered as a medicine in the Russian Federation but is not licensed by the MHRA, EMA or FDA.
Regulatory & compliance notice
This product is supplied strictly for in-vitro laboratory research. It is not a licensed medicine in the United Kingdom, is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency for human or veterinary use, and is not intended to diagnose, treat, cure or prevent any disease. Nothing on this page constitutes medical advice.
External links point to primary literature or regulatory records and open in a new tab. Citations are provided so the reader can independently verify every factual claim made on this page. Last reviewed 22 July 2026.